loader image

LATVIAN

BIOMEDICAL

RESEARCH AND STUDY CENTRE

RESEARCH AND EDUCATION IN BIOMEDICINE FROM GENES TO HUMAN

All projects
EU Structural Funds 2007-2013
1.1. Eiropas Sociālais fonds

1DP/1.1.1.2.0/09/APIA/VIAA/150 Slimību patoģenēzes ģenētisko un molekulāro mehānismu izpēte un jaunu terapijas un diagnostikas līdzekļu izstrāde

2013/0023/1DP/1.1.1.2.0/13/APIA/VIAA/037 Pretvēža terapijas rezistences molekulāro un celulāro mehānismu izpēte

2013/0039/1DP/1.1.1.2.0/13/APIA/VIAA/038 Arheoloģiskajos izrakumos iegūtā Latvijas antropoloģiskā materiāla paleopataloģiskā un molekulāri ģenētiskā izpēte

2013/0026/1DP/1.1.1.2.0/13/APIA/VIAA/006 Dabasvielu analogu totālā sintēze un pretvēža aktivitātes izpēte

1.2. Eiropas Reģionālās attīstības fonds
2.1.1.2.1. pasākums

2011/0045/2DP/2.1.1.3.1./11/IPIA/VIAA/001 Farmācijas un biomedicīnas Valsts nozīmes pētniecības centra zinātniskās infrastruktūras attīstība

2.1.1.2. pasākums

2DP/2.1.1.2.0/10/APIA/VIAA/004 Latvijas Biomedicīnas pētījumu integrācija Eiropas zinātnes telpā

2015/0001/2DP/2.1.1.2.0/14/APIA/VIAA/009 Starptautiskās sadarbības projektu pieteikumu izstrāde biomedicīnas jomā

2.1.1.1. pasākums

2010/0311/2DP/2.1.1.1.0/10/APIA/VIAA/022 Jaunu DNS diagnostikas testu izstrāde un validācija lietošanai klīniskajā praksē

2010/0223/2DP/2.1.1.1.0/10/APIA/VIAA/025 Iedzimtu neiromuskulāro slimību jaunu diagnostisko testu izstrade

2010/0312/2DP/2.1.1.1.0/10/APIA/VIAA/032 Sortāzes inhibitoru atlase antimikrobiālās terapijas nolūkiem

2010/0231/2DP/2.1.1.1.0/10/APIA/VIAA/044 Uz autoantivielu noteikšanu balstītu ļaundabīgo audzēju diagnostikas un prognostikas testu izstrāde

2010/0211/2DP/2.1.1.1.0/10/APIA/VIAA/048 Jaunas universālas hepatīta B rekombinantās vakcīnas prototipa izstrāde

2010/0314/2DP/2.1.1.1.0/10/APIA/VIAA/052 Vīrusveidīgo daļiņu nanotehnoloģija zāļu un diagnostikas līdzekļu transportstruktūru izstrādei

2010/0310/2DP/2.1.1.1.0/10/APIA/VIAA/069 Jaunu G-proteīnu saistošo receptoru farmakoloģisko testa komplektu izstrāde aktīvo vielu monitoringam

2010/0230/2DP/2.1.1.1.0/10/APIA/VIAA/075 Jauns hepatīta B vīrusa infekcijas modelis un pretvīrusa līdzekļu izvērtēšanas tehnoloģija

2010/0233/2DP/2.1.1.1.0/10/APIA/VIAA/076 Prognostiska imūnterapijas lietderīguma un efektivitātes testēšana: metodes izveide personalizētai imūnterapeitisko preparātu pielietošanai onkoloģijā

2010/0261/2DP/2.1.1.1.0/10/APIA/VIAA/155 Efektīvu augļaugu atveseļošanas paņēmienu un jaunu patogēnu diagnostikas komponenšu izstrāde vīrusbrīva stādāmā materiāla iegūšanai

2010/0224/2DP/2.1.1.1.0/10/APIA/VIAA/164 Jauna tipa terapeitisko anti-HCV individualizēto vakcīnu prototipu izstrādāšana

2013/0042/2DP/2.1.1.1.0/13/APIA/VIAA/002 Pētījumi jaunu ģenētisko un imūndetekcijas diagnostikas metožu izveidei

2013/0053/2DP/2.1.1.1.0/13/APIA/VIAA/006 Tehnoloģijas izstrādne augstas kvalitātes vīrusveidīgo uz HBV kor-antigēna balstītu nanostruktūru iegūšanai

2014/0021/2DP/2.1.1.1.0/14/APIA/VIAA/058 Jaunu in vitro diagnostikas un prognostiskas līdzekļu izstrāde individualizētai audzēju un mitohondriālo saslimšanu ārstēšanai

2014/0014/2DP/2.1.1.1.0/14/APIA/VIAA/013 VLP tehnoloģijas pielietojums vakcīnas prototipu iegūšanai pret zoonotisko slimību izraisītājiem

2014/0012/2DP/2.1.1.1.0/14/APIA/VIAA/038 Jauna cikliska augšanas hormona preparāta sintēze un validācija

2.1.1.3.3. pasākums

2015/0023/2DP/2.1.1.3.3/15/IPIA/VIAA/005 Latvijas Biomedicīnas pētījumu un studiju centra zinātniskās izcilības un institucionālās attīstības veicināšana

2.1.1.3.2. pasākums

2010/0239/2DP/2.1.1.3.2/10/IPIA/VIAA/001 Vienota nacionālas nozīmes Latvijas akadēmiskā pamattīkla zinātniskās darbības nodrošināšanai izveide

L-KAP-12-0005 Farmācijas un saistīto nozaru klastera dalībnieku sadarbības veicināšana nozares produktivitātes paaugstināšanai un eksportspējas attīstīšanai, izmantojot kombinēto stratēģiskās plānošanas, kooperatīvās loģistikas un mārketinga un specializētās pētnieciski-tehnoloģiskās infrastruktūras metodi

EU Structural Funds 2014-2020
Measure 1.1.1.1. “Support for applied research”

First selection round projects

1.1.1.1/16/A/044 Assessment of magnitude and importance of vectorborne Babesiosis in Latvia: epidemiological and diagnostic approach

1.1.1.1/16/A/054 Diagnostic and immunoprotective potential of influenza virus hemagglutinin stalk peptide: generation of novel vaccine prototypes

1.1.1.1/16/A/055 Development of orphan G-protein coupled receptor peptidic ligand identification system

1.1.1.1/16/A/066 Molecular markers of pituitary tumor development, progression and therapy response

1.1.1.1/16/A/091 Investigation of an interplay between multiple determinants influencing response to metformin: search for reliable predictors for efficacy of type 2 diabetes therapy

1.1.1.1/16/A/101 The impact of burial environmental microbiome on biomolecular archeology and the ancient tuberculosis research

1.1.1.1/16/A/104 Obtaining and characterization of virus-like particles of novel RNA phages

1.1.1.1/16/A/107 Development of new antimicrobial agents targeting Gram-positive bacterial sortase A

1.1.1.1/16/A/211 Molecular design of new luminescent compounds for diagnostic purposes

1.1.1.1/16/A/272 Long term effects of H.pylori eradication on Gastro intestinal tract microbiome and development of screening system for detection of extended-spectrum beta-lactamase coding genes within feces samples

Secound selection round projects

1.1.1.1/18/A/026 Studies on Ribes plants, Cecidophyopsis mites and Blackcurrant Reversion virus for sustainable resistance breeding and cultivation of Ribes

1.1.1.1/18/A/099 Understanding the biology of the minimal residual disease after targeted therapy of BRAF mutant melanoma

1.1.1.1/18/A/084 Clinical utility of extracellular vesicle-enclosed human and microbial transcriptome

1.1.1.1/18/A/089 RNA molecular determinants in development of pituitary adenoma

1.1.1.1/18/A/092 Role of miRNAs in the host-gut microbiome communication during metformin treatment in the context of metabolic disorders

1.1.1.1/18/A/096 The determination of rare inherited diseases’ causative mechanisms using whole genome sequencing approach

1.1.1.1/18/A/097 Functional and genetic research of rare unidentitied neuromuscular disorders

Third selection round projects

1.1.1.1/19/A/036 Interaction and dynamics of intestinal IgA and gut microbiome profile during antidiabetic therapy

Fourth selection round projects

1.1.1.1/20/A/045 Development of a novel microfluidic device for label-free quantification of prostate cancer-derived extracellular vesicles and analysis of their RNA content (PROCEX)

1.1.1.1/20/A/046 Whole genome sequencing of tuberculosis for routine clinical use in Latvia: evidence-based design and concept evaluation

1.1.1.1/20/A/047 DECIDE – Development of a dynamic informed consent system for biobank and citizen science data management, quality control and integration

1.1.1.1/20/A/048 Usage of conservative borrelia protein as vaccine target

1.1.1.1/20/A/124 Testing of patient-derived stem cell extracellular vesicles loaded with drugs in a personalized lung-cancer on-chip platform (LoC4Ev)

1.1.1.1/20/A/126 An integrated population based Latvian genome reference and its applicability to personal risk estimation for metabolic traits

Fifth selection round projects

1.1.1.1/21/A/029 Identification of molecular determinants associated with the risk for various COVID-19 long term effects: a comprehensive cohort-based study in Latvian population. (POST-COVID-TRACK)

1.1.1.1/21/A/033 Enclosed lung on a chip system development suitable for respiratory disease research in BSL3 and microgravity systems. (LoCBox)

1.1.1.1/21/A/044 The development of an efficient pilot-scale leghemoglobine production technology, based on recombinant Pichia pastoris and Kluyveromyceslactis fed-batch fermentations (BioHeme)

1.1.1.1/21/A/050 Large area deposition technologies of multifunctional antibacterial and antiviral nanocoatings

1.1.1.1/21/A/079 AI-improved organ on chip cultivation for personalised medicine (AImOOC)

Measure 1.1.1.2. “Post-doctoral Research Aid”

First selection round projects

1.1.1.2/VIAA/1/16/203 Engineering of extracellular vesicles to transfer tumor suppressor miRNA to cancer cells

1.1.1.2/VIAA/1/16/144 Structural and functional studies of Lyme disease agent Borrelia burgdorferi outer surface proteins to reveal the mechanisms of pathogenesis with the intention to create a new vaccine

1.1.1.2/VIAA/1/16/135 sRNAflow – a tool for analysis of small RNA-seq data

1.1.1.2/VIAA/1/16/128 Investigation of interaction of smoked dietary products with gut microbiome

Secound selection round projects

1.1.1.2/VIAA/2/18/292 Role of natural killer cells in the therapeutic efficacy of oncolytic measles virus

1.1.1.2/VIAA/2/18/286 Optimization of novel plant derived enzyme expression in microorganisms for biotechnological application

1.1.1.2/VIAA/2/18/285 Combination of system and molecular biology approaches for discovery and characterization of plant enzymes for industrial processes

1.1.1.2/VIAA/2/18/287 Identification of clinical subgroups of Type 2 diabetes mellitus and application of pharmacogenetics in development of personalized antidiabetic therapy

Third selection round projects

1.1.1.2/VIAA/3/19/463 The role of “mitotic slippage” in the origin of amoeboid metastatic cell in therapy resistant cancers

1.1.1.2/VIAA/3/19/464 Structural and kinetic studies of human carbonic anhydrases as multiple drug targets

1.1.1.2/VIAA/3/19/462 Structural and functional studies of Ryegrass mottle virus-encoded proteins

1.1.1.2/VIAA/3/19/460 Association of human intestinal and blood microbiome composition with general state of health and mortality within population of Latvia

Fourth selection round projects

1.1.1.2/VIAA/4/20/704 Structural studies of a Borrelia burgdorferi bacteriophage

1.1.1.2/VIAA/4/20/705 Development of a bacterial microcompartment-based nanoreactor platform for metal-containing nanoparticle synthesis

1.1.1.2/VIAA/4/20/728 Evaluation the potential of virus-like particles carrying carbonic anhydrase IX as anti-cancer vaccine

Measure 1.1.1.4. “Development of the R&D Infrastructure in Fields of Smart Specialisation and Strengthening of Institutional Capacity of Scientific Institutions”.

1.1.1.4/17/I/009 Infrastructure of the Latvian Biomedical Research and Study Center for the strengthening of research and technology transfer capacities in the fields of biomedicine and biotechnology

Measure 1.1.1.5. “Support of International Cooperation Projects in Research and Innovation”.

1.1.1.5/18/I/006 Support for the integration of the Latvian Biomedical Research and Study Centre into the European Research Area and Infrastructure objects

1.1.1.5/20/A/002 European resercher Night in Latvia 2020

Measure 1.2.1.2. “Support of Improvement of Technology Transfer System”.

First selection round projects

KC-PI-2017/23 Precision medicine test for the therapeutic decisions and monitoring of treatment response in breast cancer

Secound selection round projects

KC-PI-2017/83 Plant virus-derived vaccine technology platform

KC-PI-2017/84 Development of anti-Lyme disease vaccine candidate

Third selection round projects

KC-PI-2020/23 Development of anti-myostatin vaccine for promotion of livestock animal muscle growth

KC-PI-2020/30 Dynamic human microbiome data platform and interpretation tool for personalized health recommendations

Measure 8.2.2. “Strengthen academic staff of higher education institutions in areas of strategic specialisation”.

8.2.2.0/20/I/006 Strengthening LU doctoral capacity under the new doctoral model

8.2.2.0/20/I/008 Strengthening Riga Technical University and Banking University doctoral candidates and academic staff capacity in areas of strategic specialisation

Recovery and Resilience Facility

4.1.1.r.0/3/22/I/VM/001 Establishment of the Latvian Population Genome Reference

2.1.3.1.i.0/2/23/I/CFLA/001 Development of an information technology infrastructure for the Latvian residents’ reference genome storage and provision of access

EU Programmes
7. Framework Programme

BBMRI- Large Prospective Cohorts (BBMRI-LPC)

Vector-borne Risks for Europe: Risk assessment and control of West Nile and Chikungunya virus (VECTORIE)

Development of a universal influenza vaccine based on tandem core technology

Horizon 2020

ADOPT – implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC

European Researchers Night in Latvia 2018-2019

Integration of knowledge and biobank resources in comprehensive translational approach for personalized prevention and treatment of metabolic disorders INTEGROMED

Beyond 1M Genomes B1MG

Horizon Europa

Harnessing the marine microbiome for novel sustainable biogenics and ecosystem services (BlueRemediomics)

Digital Europe

Genomic Data Infrastructure (GDI)

EU4Health

Building the EU Cancer and Public Health Genomics platform (CAN.HEAL)

TRANSCAN

Identification of genetic markers involved in development of metastases and second cancers in melanoma (GENMEL)

TRANSCAN 2

Exploitation of extracellular vesicles for precision diagnostics of prostate cancer (PROSCANEXO)

Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors (NExT)

ERA. NET RUS Plus

Alphavirus-based delivery of chitinase-like-protein gene for anti-tumour programing of macrophages (Alpha-Chit)

ERA-NET EuroNanoMed II

Universal Nano-enhancer for a new multiplexing Surface Plasmon Resonance Imaging analysis of miRNAs in multiple sclerosis (NanoPlasmiRNA)

M-era.Net

Nanoparticle Transfer Through Endothelial Barrier (NanoTENDO)

Neurodegenerative Disease Research (JPND)

Oligomer – Focused Screening and Individualized Therapeutics to target Neurodegenerative Disoders (OligoFIT)

EUROSTARS 2

Challenging African Swine Fever outbreaks with innovative VLP-based vaccines” (ASF-INNOVAC)

ERA PerMed

Glioma invasion assays as a predictive tool for personalized glioma medicine” (Glioma-PerMed)

EEA/ Norwegian financial mechanisms
2009-2014

NFI/R/2014/045 Cancer-derived extracellular vesicles: function and clinical applications in prostate cancer

NFI/R/2014/051 Image-guided cancer gene therapy in combination with advanced chemotherapeutics

2014-2021

S-BMT-21-11 (LT08-2-LMT-K-01-060) GUT-BLOOD-LIVER AXIS: CIRCULATING MICROBIOME AS NON-INVASIVE BIOMARKER FOR INFLAMMATORY BOWEL DISEASE (IBD) AND PRIMARY SCLEROSING CHOLANGITIS (PSC) [Blood-Biome]

EEA-RESEARCH-164 Exploring the molecular mechanisms behind the effects of physical exercise on breast cancer prevention (CancerBeat)

State research programme

State research programme to lessen the effects of COVID-19

VPP-COVID-2020/1-0014

VPP-COVID-2020/1-0016

VPP-COVID-2020/1-0004

VPP-COVID-2020/1-0008

VPP-COVID-2020/1-0023

VPP-COVID-2020/1-0025

State research programme Innovation Fund – Sectoral Research Programme

VPP-EM-FOTONIKA-2022/1-0001

VPP-EM-BIOMEDICĪNA-2022/1-0001

Other projects
OSMOZE

Structural studies of antigens coupled to virus-like particles by solid-state NMR

Mutual Funds Latvian-Lithuanian-Taiwanese Cooperation Projects

Role of ryanodine receptors in neuroendocrine tumour development: implications in electrophysiological and molecular tumorigenesis mechanisms

Immunomodulating properties of bacteriophage derived dsRNA of different size and their use as vaccine adjuvants

Functional model for the mitochondrial disease evaluation and biomarker development

Kuņģa vēža asociēto autoantivielu testa izveide un validēšana agrīnai kuņģa vēža diagnostikai

BIOCODEX

Effect of the Nordic diet on composition and functional profile of faecal microbiota and symptoms of fatigue in patients with mild and moderate ulcerative colitis

The Baltic-German University Liaison Office supported project

Function Determining Chromatin Self-Organization after Heregulin Stimulation of Gene Activities and Cancer Cell Differentiation

The Childrens's Hospital Foundation project

Development of precision medical techniques for the treatment of child malignancies

Latvian - Ukraine cooperation project

Impact of bacteriophage-derived dsRNA on macrophages in the context of COVID-19 pandemic

Fundamental and Applied Research Projects
2018-2020

lzp-2018/1-0156 Investigation of the chemokine receptors CCR1 and CCR2 and EBV infection aimed on disclosure of new markers that can predict the high risk for progression of chronic lymphocytic leukemia

2018/1-0395 Gender, sex and status in Iron Age Latvia (7th – 12th centuries AD)

lzp-2018/1-0180 The characterization and analysis of mitochondrial DNA mutations and variants of unknown significance using transmitochondrial cytoplasmic hybrid cell models

lzp-2018/1-0208 Functional programming of tumor-associated macrophages with viral immunotherapy vectors in breast cancer model

lzp-2018/1-0269 Prostate cancer-derived extracellular vesicles as liquid biopsies and therapeutic targets

lzp-2018/2-0088 Mathematical model of pharmacokinetics for personalized optimization of metformin therapy

lzp-2018/2-0059 Interplay of Environmental and Genetic Factors in the Immunologic Mechanisms of Thyroid Autoimmune Diseases

lzp-2018/2-0171 Ethically and socially responsible governance of research biobanks in Latvia: analysis of opinions of public, donors and researchers

2020-2022

lzp-2019/1-0116 Investigation of the origin and dynamics of human blood microbiome, and its role in chronic disease

lzp-2019/1-0131 Development of plant virus-based bacterial vaccine production platforms

lzp-2019/1-0142 Microfluidic field flow fractionation for high throughput extra-cellular vesicle separation

lzp-2019/1-0225 Multidisciplinary study of community-acquired sepsis survivors in Latvia

lzp-2019/1-0075 Characterization of general and mastitis susceptibility genetic background for Latvia’s (indigenous) local breeds of ruminants

2021-2023

lzp-2020/1-0050 Tuberculosis treatment: exploring the perspectives for personalised therapy

lzp-2020/1-00138 Dissecting the associations between glucose variability, intestinal derangements and progression of diabetic nephropathy in type 1 diabetes

lzp-2020/1-0151 Low-coverage whole-genome sequencing analysis of polygenic mechanisms of high cholesterol levels in patients with clinically diagnosed or possible familial hypercholesterolemia

lzp-2020/1-0163 Characterization and dynamics of seed-associated microbiome in weed soil seed-bank

2020-2021

lzp-2020/2-0082 Evolutionary adaptation of non-conventional industrial yeasts Kluyveromyces marxianus to acetic acid stress and evaluation of adaptation mechanisms

lzp-2020/2-0369 Bacteriophage–derived dsRNA as a potential agent against coronovirus

lzp-2020/2-0371 Genetic investigation of urban Northern goshawks (Accipiter gentilis) in Riga – launching into wild population genomics

lzp-2020/2-0372 Strengthening GPCR functional research through improvement of novel peptidic ligand identification system

lzp-2020/2-0373 Characterization of DNA bacteriophages isolated from the insect intestine microflora

lzp-2020/2-0374 Deciphering the genetic mechanisms of the individuals with isolated cleft palate by whole genome sequencing

lzp-2020/2-0376 Pathogenicity of human Hepatitis C virus relying on enzymatic properties of viral RNA-dependent RNA-polymerase

lzp-2020/2-0378 Structural and immunological characterization of potential Lyme disease vaccine candidates

lzp-2020/2-0380 Research of extracellular vesicle content from gut microbiome and its’ role in cancer development by applying gut on chip system

2022-2024

lzp-2021/1-0041 Research of microbiota-derived extracellular vesicle role on breast cancer by using gut-breast cancer axis on a chip

lzp-2021/1-0050 Molecular design of DNA phage-derived endolysins for targeting Gram-negative bacteria

lzp-2021/1-0056 Investigate biotic stress induced inter-plant molecular signals and responses in mycorrhizal fungi-connected plants

lzp-2021/1-0059 HBc VLP-based platform for the development of a recombinant vaccine prototype against SARS-Cov-2

lzp-2021/1-0068 Structural and functional characterization of the paralogous gene family PFam12 member proteins from the Lyme disease causing agent Borrelia burgdorferi to determine their role in the pathogenesis of Lyme disease

lzp-2021/1-0275 Gut microbiota composition in relation to extrinsic factors and health status in infants and toddlers: prospective analysis of faecal microbiota composition by meategenomic sequencing in children up to 36 months of age

lzp-2021/1-0283 Programming of breast cancer microenvironment to create a ”hot” immune-responsiveness in cancer

lzp-2021/1-0584 Development of carbonic anhydrase IX test biosensor for cancer screening

2023-2025

lzp-2022/1-0102 Targeting autoimmune mechanisms for prevention of gastric neuroendocrine tumours

lzp-2022/1-0111 Structural and functional studies of proteome encoded by three novel temperate DNA bacteriophages isolated from Antarctic soil

lzp-2022/1-0119 Microbiome of hair follicle and its role in pathogenesis of skin diseases

lzp-2022/1-0299 Multidimensional characterisation of plastic waste biodegradation mechanisms in the municipal solid waste landfill

lzp-2022/1-0386 Role of genetic makeup in the modulation of early prediabetic dysglycemia and its interaction with gut microbiome

lzp-2022/1-0629 Development of vaccine prototype for autoimmune diseases caused by chronic inflammation, proof-of-concept study

lzp-2022/1-0373 Extremely low frequency electromagnetic field as temporary enhancer for production of extracellular vesicles from mesenchymal stem cells in bioreactor

lzp-2022/1-0283 Role of mycorrhizal fungi in inter-plant signalling and pest tolerance of hybrid aspen

lzp-2022/1-0179 Role of endophytic microbiota in the anti-viral activity of S. Nigra against type A influenza and SARS-CoV-2

lzp-2022/1-0059 Viking Age in Latvia: an interdisciplinary study

2024-2026

lzp-2023/1-0070 Development of a vaccine prototype for the treatment and prevention of periodontitis as a proof-of-concept study

lzp-2023/1-0378 Modelling celiac disease on-a-chip

lzp-2023/1-0422 MetHerb: Enhancing the efficacy and tolerability of metformin in the analysis of gut microbiome by add-on polyherbal formulation